Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.
Dr. Patrick Wen
Advertisement
Wen was the senior author of a study published in the Journal of Clinical Oncology that found monotherapy with Modeyso to be well-tolerated, with durable and clinically meaningful effectiveness among patients with recurrent H3 K27M-mutant diffuse midline glioma.
Articles by Dr. Patrick Wen
The accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation, is a step in the right direction but more work remains.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Breaking Down Advancements in Prostate Cancer Care
2
FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer
3
When One Blood Draw Could Tell More: A Look at the Cancerguard Test
4
Shared Loss Leads to Lifelong Friendship in Rare Cancer Caregiving
5
